PrimeAI raises $13.8M Series A to scale AI clinical trials
What's the deal? Chinese digital healthcare firm Hangzhou Purui Life Science Technology, which operates globally as PrimeAIDealroom has a profile for this one. Try Dealroom →, has closed a Series A round worth nearly 100 million yuan ($13.8 million).
State-backed CICC Capital led the round. Sumitomo Corporation Asia Capital and Suzhou Gaoxin Rongsheng co-invested, with China RenaissanceDealroom has a profile for this one. Try Dealroom → as exclusive financial advisor.
PrimeAI will use the funds to scale its AI-native clinical trial network and acquire traditional clinical research businesses.
Other priorities: refining its AI agent clusters, funding specialised services, and expanding its global commercial footprint.
Why now? Pharmaceutical companies across the Chinese mainland are racing to cut prohibitive research and development costs.
Advanced data modelling and algorithmic infrastructure are becoming vital to clinical trial networks as a result.
What could go wrong? Cross-referencing electronic medical records with electronic data capture systems demands tight data governance.
Standardising that data for international regulatory filings is complex, and any gaps could slow approvals or undermine trust in the platform.
The signal: Technology-driven clinical providers are shortening enrolment cycles and reshaping how trials run.
Backing from state and corporate investors signals confidence that AI will become core infrastructure for global clinical research.
Read more: en.tmtpost.com
Image credit: NavyMedicine
